GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development

Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site ...

GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs

By Bhanvi Satija and Raechel Thankam Job LONDON, July 28 (Reuters) - GSK launched a £1.9 billion ($2.52 billion) cost-savings ...

GSK Strikes AI Deal With UK Biotech to Boost Early Pipeline

GSK Plc agreed another deal with British biotech Relation Therapeutics Ltd. to use artificial intelligence to speed up drug development.
Reuters

GSK, partner iTeos scrap development of lung cancer therapy

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug, ...
Morningstar

Hengrui Pharma Signs Milestone Drug-Development Deal With GSK

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
Nasdaq

iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno ...

GOSSELIES, Belgium and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics (NASD: ITOS) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement to co-develop and co-commercialise ...
Bloomberg L.P.

GSK’s New CEO Wants to Speed up Drug Development, Eyes Deals

GSK Plc’s new chief executive officer plans to speed up research and development and look for acquisitions as the British drugmaker tries to convince investors it can offset a looming patent cliff.